Panalgo , a leading health analytics company, announced today that its Instant Health Data (IHD) platform will be used by the European Medicines Agency (EMA) to facilitate real world data analysis.
EMA will use IHD to perform rapid analyses of internally accessible electronic health data (EHD) (currently data from UK, France and Germany) to more rapidly examine drug utilization, assess safety / efficacy, understand how treatments work in settings in the real world and support public health efforts in the European Union (EU).
EMA scientific committees will benefit from faster support for informed decision-making at the population level, including the risk of benefits of medicines, life cycle analyses of products and other clinical insights to better support public health goals.
To choose the analysis software, EMA conducted a rigorous evaluation of IHD, as well as several other platforms, including proofs of concept, in-depth hands-on analysis, and verification of results. IHD received the highest score in the evaluation.
“We are delighted to partner with the EMA to support its mission of ensuring the efficacy and safety of medical products across the EU. Our company is strongly aligned with the EMA’s public health goals, for which timely ideas based in evidence they are of particular importance, especially during this COVID-19 pandemic, “said Joseph Menzin , PhD, CEO of Panalgo. “Most of Panalgo’s life sciences clients already rely on IHD to perform rapid analyzes that support regulatory initiatives. The IHD platform will be a valuable tool to enable collaboration between drug manufacturers and regulatory agencies, such as EMA. ”
Panalgo is also pleased to announce the opening of its first European office, in Amsterdam, which has experienced analysts to further support the partnership with the EMA, as well as its growing European client base.